Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

• Published in: Journal for immunotherapy of cancer Vol. 2; no. 1; p. 34
• Main Authors: Mandl, Stefanie J, Rountree, Ryan B, Dela Cruz, Tracy B, Foy, Susan P, Cote, Joseph J, Gordon, Evan J, Trent, Erica, Delcayre, Alain, Franzusoff, Alex
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.10.2014; BMJ Publishing Group LTD; BioMed Central
• Subjects: Analysis; Antigens; Care and treatment; Cytotoxicity; Drug therapy; FDA approval; Flow cytometry; Immune response; Immunotherapy; Interferon; Lymphocytes; Medical prognosis; Metastasis; Methods; Patient outcomes; Peptides; Prostate cancer; Tumors; Active immunotherapy; Immune correlates; Teff :Treg ratio; Heterologous prime-boost; Mechanism of action; Prostate cancer; PROSTVAC

PROSTVAC®, an active immunotherapy currently studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC), consists of a heterologous prime-boost regimen with two different poxvirus-based vectors to provoke productive immune responses against prostate specific antigen (PSA) a...